Recently, the 2022 (4th) Innovation and Development Forum was held in Beijing, co-hosted by Internet Weekly of the Chinese Academy of Sciences, the Informatization Research Center of the Chinese Academy of Social Sciences, Debenhams Consulting and eNet Research Institute. With its advanced technological advantages and outstanding contributions to the industry, DHC was awarded the 2022 Medical Big Data and Artificial Intelligence Leading Enterprise Award.

Reasons for the Award

With the dual technology engine of "Big Data + Artificial Intelligence", DHC focuses on four business scenarios, including medical big data, intelligent imaging, precision medicine and digitalization of pharmaceutical enterprises. The model aims to provide a full ecological solution for the medical, pharmaceutical and insurance industries, assisting the medical and life science industries to enter the era of intelligence and precision medicine.

Based on big data and artificial intelligence techniques, complex protein structures are predicted precisely. The transmissibility and adaptability of viral virulence formed by mutations in new coronavirus genes can be predicted in advance. It is evident that big data technology has brought great changes and breakthroughs to medicine.

With the concept of "creating unlimited health for the nation with the ultimate development of technology", China Medical has formed a whole chain and one-stop intelligent data processing capability. This model has broken through the barriers of interconnection of clinical data, imaging data and histology data, and successfully built several national, disease-specific and multimodal big data platforms, which contributes to the achievement of the goal of a healthy China. In particular, the diagnosis and treatment of major diseases and high-incidence chronic diseases can make high-quality medical resources available to the public, and promote a number of breakthrough medical clinical and scientific research achievements.

The company has led the way in innovation and creativity in medical big data and artificial intelligence companies with impressive achievements.

(Cited from Internet Deep Internet Weekly official accounts)

Since its establishment in 2016, DHC has formed a multimodal, full-system, huge data governance capability and AI application capability. It promotes the digitalization and intelligent development of China's medical industry through the comprehensive implementation of multi-level and multi-scene big data AI solutions. DHC provides multi-dimensional and development-adapted products and solutions for different types and levels of hospitals.

To better practice the national graded diagnosis and treatment program and promote the development and construction of grassroots hospitals, DHC has formed an innovative intelligent imaging cloud model as the backbone to create an imaging and radiotherapy medical association model with top hospitals as the main body and targeted and close support to regional hospitals at all levels. This can promote the decentralization of high-quality medical resources and enhance medical equity and accessibility.

At present, the company has developed two radiotherapy medical association demonstration projects with Cancer Hospital of Chinese Academy of Medical Sciences as the national core and Hunan Cancer Hospital as the provincial core, which have obtained positive results.

For clinical hospitals, the company provides one-stop solutions for CDSS, imaging, pathology AI, radiotherapy cloud, MDT and specialized disease management around the core process of oncology from "screening-diagnosis-treatment-follow-up". It has been implemented in Cancer Hospital of Chinese Academy of Medical Sciences, General Hospital of Chinese People's Liberation Army and the First Affiliated Hospital of Zhengzhou University.

For research hospitals, DHC provides hospital-wide/departmental-level multimodal clinical, imaging, and multi-omics big data platforms, and boasts services such as drug clinical research. Through three consecutive phases of cooperation, the company has formed a hospital-wide big data platform with Southern Hospital of Southern Medical University for continuous construction. The model has been selected as a big data demonstration application project and a typical case of digital health by the Ministry of Industry and Health Care Commission.

Since its establishment six years ago, DHC has always been deeply involved in the whole clinical process, including screening, diagnosis, treatment, management, and research, and continues to promote both clinical value and research quality of medical institutions.

For future planning, the company will also adhere to the 134 business strategy to further deepen the product and solution system that empowers the medical institutions' diagnosis and treatment capabilities. On the one hand, the company will do a fine job of localized R&D and innovation of independent intellectual property rights; on the other hand, the company will cooperate with internationally renowned medical and technical institutions in order to better provide Chinese users with technologies and services that are in line with the world and suitable for national conditions.

Given the development and progress of technology, the medical industry is nurturing an unprecedented change. To meet the era of intelligent and precise medical care, DHC will adopt artificial intelligence and big data as the core driving force to improve the treatment effect of patients, enhance the efficiency of doctors, and support the solution of new medical reform issues such as imbalance of medical resources.